| Attributes | Values |
|---|
| rdf:type
| |
| description
| - wetenschappelijk artikel (nl)
- наукова стаття, опублікована в лютому 1993 (uk)
- article scientifique publié en 1993 (fr)
- im Februar 1993 veröffentlichter wissenschaftlicher Artikel (de)
- artículu científicu espublizáu en febreru de 1993 (ast)
- artikull shkencor i botuar më 01 shkurt 1993 (sq)
- scientific article published on 01 February 1993 (en)
|
| publication date
| |
| publication date
| |
| language of work or name
| |
| language of work or name
| |
| author name string
| |
| author name string
| - L Rubinstein
- P A Thomas
- R Feld
|
| rdfs:label
| - Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group (en)
- Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group (nl)
- Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group (sq)
|
| skos:prefLabel
| - Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group (en)
- Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group (nl)
- Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group (sq)
|
| name
| - Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group (en)
- Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group (nl)
- Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group (sq)
|
| title
| |
| title
| - Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group (en)
|
| page(s)
| |
| page(s)
| |
| instance of
| |
| instance of
| |
| main subject
| |
| main subject
| |
| PubMed ID
| |
| PubMed ID
| |
| PubMed ID
| |
| published in
| |
| published in
| |
| issue
| |
| volume
| |
| issue
| |
| volume
| |
| DOI
| |
| DOI
| |
| DOI
| |
| is about
of | |
| is cites work
of | - Postoperative adjuvant therapy for stage IB non-small-cell lung cancer
- A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer: North-east Japan Study Group for Lung Cancer Surgery
- Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data
- Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group
- Evidence-based medicine in the treatment of non-small-cell lung cancer
- Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJS
- Therapy for stage I and stage II non-small cell lung cancer
- Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).
- Induction chemotherapy before surgery for early-stage lung cancer: A novel approach
- Adjuvant chemotherapy for resected non-small cell lung cancer.
- Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection.
- Prospective comparison of radiologic, thoracoscopic, and pathologic staging in patients with early non-small cell lung cancer
- Validation of a Modified Rotterdam Symptom Checklist for use with cancer patients in the United States
- Surgical Decisions for Early Stage, Non–Small Cell Lung Cancer: Which Racially Sensitive Perceptions of Cancer Are Likely to Explain Racial Variation in Surgery?
- Patients with stage I non-small cell lung carcinoma at postoperative risk for local recurrence, distant metastasis, and death: implications related to the design of clinical trials
- Adjuvant therapy for resected non-small cell lung cancer
- Adjuvant chemotherapy for non-small cell lung cancer
- Adjuvant chemotherapy for resected early-stage non-small cell lung cancer
- The role of chemotherapy in early non-small-cell lung cancer management.
- New prognostic factors in resectable non-small cell lung cancer
- Prognostic factors in clinical stage I non-small cell lung cancer
- Chemotherapy in Stage I/II NSCLC and projects of the EORTC-Lung Cancer Group for Early Stage Lung Cancer
- Adjuvant therapy for resected non-small-cell lung cancer: past, present, and future
- Chemotherapy for advanced non-small cell lung cancer
- Post-operative adjuvant thoracic radiotherapy for patients with completely resected non-small cell lung cancer with nodal involvement: outcome and prognostic factors.
- Stage-directed treatment guidelines
- Meta-analysis of postoperative adjuvant chemotherapy without radiotherapy in early stage non-small cell lung cancer
- Neoadjuvant and adjuvant trials in non-small cell lung cancer
- Multi-modality treatment of non-small cell lung cancer
- Consensus conference on medical treatment of non-small cell lung cancer: adjuvant treatment
- Adjuvant therapy for resected non-small-cell lung cancer: recent advances, emerging agents, and lingering questions.
- Non-small-cell lung carcinoma. Current and future therapeutic management
- Common cancers--immunotherapy and multidisciplinary therapy: Parts III and IV.
- Induction Therapy for Early-Stage Lung Cancer? The Rationale Behind the Question
- Postoperative chemotherapy for resected non-small-cell lung cancer
- Diagnosis and management of early lung cancer
- Chemotherapy for early stage non-small cell lung cancer.
|
| is cites work
of | |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)